SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's
chief executive officer, will present at the Citi Investment Research
Global Healthcare Conference in New York City on May 22, 2008 at 9:30 a.m.
EDT.
To access the live webcast or the subsequent archived recording, log on
to http://www.anesiva.com, go to the Investors page, and click on Events.
Please connect to Anesiva's website several minutes prior to the start of
the webcast to ensure adequate time for any software download that may be
necessary.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to
be the leader in the development and commercialization of novel
pharmaceutical products for pain management. The company has one
FDA-approved product, Zingo(TM), for the reduction of pain associated with
peripheral venous access procedures in children ages three to 18. In
clinical trials, the most common adverse reactions to Zingo were redness
(erythema), red dots (petechiae) and swelling (edema). The second product
in Anesiva's pipeline, Adlea(TM), reduces pain after only a single
administration for weeks to months based on mid-stage clinical trials for
site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based
in South San Francisco, CA. For more information about Anesiva's leadership
in the development of products for pain management, and an overview of the
clinical challenges being addressed by its product candidates, go to
http://www.anesiva.com.
See Also
- Who Else Wants To Lose Weight Naturally?
- ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
- Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
- Waterfront Media Goes Global : Waterfront Media Partners with Tesco Diets, the Leading Online Healthy Eating Site in UK
Via: Healthcare
0 коментарі:
Post a Comment